18q Loss of Heterozygosity in Microsatellite Stable Colorectal Cancer is Correlated with CpG Island Methylator Phenotype-negative (CIMP-0) and Inversely with CIMP-low and CIMP-high

DSpace/Manakin Repository

18q Loss of Heterozygosity in Microsatellite Stable Colorectal Cancer is Correlated with CpG Island Methylator Phenotype-negative (CIMP-0) and Inversely with CIMP-low and CIMP-high

Citable link to this page

. . . . . .

Title: 18q Loss of Heterozygosity in Microsatellite Stable Colorectal Cancer is Correlated with CpG Island Methylator Phenotype-negative (CIMP-0) and Inversely with CIMP-low and CIMP-high
Author: Kawasaki, Takako; Kirkner, Gregory J; Ogino, Shuji; Ohnishi, Mutsuko; Fuchs, Charles Stewart

Note: Order does not necessarily reflect citation order of authors.

Citation: Ogino, Shuji, Takako Kawasaki, Gregory J. Kirkner, Mutsuko Ohnishi, and Charles S. Fuchs. 2007. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high. BMC Cancer 7: 72.
Full Text & Related Files:
Abstract: Background: The CpG island methylator phenotype (CIMP) with widespread promoter methylation is a distinct epigenetic phenotype in colorectal cancer, associated with microsatellite instability-high (MSI-high) and BRAF mutations. 18q loss of heterozygosity (LOH) commonly present in colorectal cancer with chromosomal instability (CIN) is associated with global hypomethylation in tumor cell. A recent study has shown an inverse correlation between CIN and CIMP (determined by MINTs, p16, p14 and MLH1 methylation) in colorectal cancer. However, no study has examined 18q LOH in relation to CIMP-high, CIMP-low (less extensive promoter methylation) and CIMP-0 (CIMP-negative), determined by quantitative DNA methylation analysis. Methods: Utilizing MethyLight technology (real-time PCR), we quantified DNA methylation in 8 CIMP-specific promoters {CACNA1G, CDKN2A (p16), CRABP1, IGF2, MLH1, NEUROG1, RUNX3 and SOCS1} in 758 non-MSI-high colorectal cancers obtained from two large prospective cohorts. Using four 18q microsatellite markers (D18S55, D18S56, D18S67 and D18S487) and stringent criteria for 18q LOH, we selected 374 tumors (236 LOH-positive tumors with ≥ 2 markers showing LOH; and 138 LOH-negative tumors with ≥ 3 informative markers and no LOH). Results: CIMP-0 (0/8 methylated promoters) was significantly more common in 18q LOH-positive tumors (59% = 139/236, p = 0.002) than 18q LOH-negative tumors (44% = 61/138), while CIMP-low/high (1/8–8/8 methylated promoters) was significantly more common (56%) in 18q LOH-negative tumors than 18q LOH-positive tumors (41%). These relations persisted after stratification by sex, location, or the status of MSI, p53 expression (by immunohistochemistry), or KRAS/BRAF mutation. Conclusion: 18q LOH is correlated positively with CIMP-0 and inversely with CIMP-low and CIMP-high. Our findings provide supporting evidence for relationship between CIMP-0 and 18q LOH as well as a molecular difference between CIMP-0 and CIMP-low in colorectal cancer.
Published Version: doi://10.1186/1471-2407-7-72
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1876238/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:4727661

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters